Presumably, the CHM1‐mediated growth advantage in vitro may be reduced by a poorer supplement/support of tumor growth in vivo due to the known antiangiogenic function of this glycoprotein (Hiraki et al., 1997; Yoshioka et al., 2006). This evidence concerns the gene CNMD and neoplasm.